SIGA Technologies, Inc. Appoints Julian Nemirovsky as Director
December 11, 2020 at 04:59 pm EST
Share
On December 10, 2020 upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors of SIGA Technologies, Inc., the Board appointed Julian Nemirovsky as a director of the Company, effective immediately. Mr. Nemirovsky will serve a term through the date of the next annual meeting of the Company’s stockholders. Mr. Nemirovsky is a Senior Vice President of MacAndrews & Forbes Incorporated, a related party to SIGA.
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The Company's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. It uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.
SIGA TECHNOLOGIES, INC. 
